恶性胸膜间皮瘤的晚期和复发性免疫治疗。
Immunotherapy for advanced and recurrent malignant pleural mesothelioma.
机构信息
Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark.
Digestive Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
出版信息
Cochrane Database Syst Rev. 2024 Sep 18;9(9):CD014720. doi: 10.1002/14651858.CD014720.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of immune checkpoint inhibitors (single-agent or combination therapy) in people with advanced malignant pleural mesothelioma in a first-line or salvage setting.
摘要
这是一篇 Cochrane 综述（干预措施）的方案。其目的如下：评估免疫检查点抑制剂（单药或联合治疗）在一线或挽救治疗中晚期恶性胸膜间皮瘤患者中的疗效。
相似文献
1
Immunotherapy for advanced and recurrent malignant pleural mesothelioma.恶性胸膜间皮瘤的晚期和复发性免疫治疗。
Cochrane Database Syst Rev. 2024 Sep 18;9(9):CD014720. doi: 10.1002/14651858.CD014720.
2
Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.恶性胸膜间皮瘤中的免疫检查点抑制剂：前景与挑战
Expert Rev Anticancer Ther. 2016 Jul;16(7):673-5. doi: 10.1080/14737140.2016.1191951. Epub 2016 May 30.
3
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies.胸膜间皮瘤的免疫治疗：当前和新兴的治疗策略。
Int J Mol Sci. 2024 Oct 9;25(19):10861. doi: 10.3390/ijms251910861.
4
First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?一线双联免疫疗法：间皮瘤患者的变革之举还是炒作？
Lung Cancer. 2024 Aug;194:107891. doi: 10.1016/j.lungcan.2024.107891. Epub 2024 Jul 14.
5
Is there a role for immunotherapy in malignant pleural mesothelioma?免疫疗法在恶性胸膜间皮瘤中的作用如何？
Med Oncol. 2018 May 29;35(7):98. doi: 10.1007/s12032-018-1156-x.
6
Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.恶性胸膜间皮瘤的免疫治疗。现状与展望。
Am J Respir Cell Mol Biol. 2014 May;50(5):870-5. doi: 10.1165/rcmb.2013-0472TR.
7
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.将 PD-L1 抑制剂阿特珠单抗与 WT1/DC 疫苗联合用于上皮样恶性胸膜间皮瘤患者的标准一线治疗：Immuno-MESODEC 研究方案。
PLoS One. 2024 Jul 15;19(7):e0307204. doi: 10.1371/journal.pone.0307204. eCollection 2024.
8
Management of recurrence after initial surgery for malignant pleural mesothelioma: a mini-review.恶性胸膜间皮瘤初次手术后复发的管理：一篇综述短文
Future Oncol. 2015;11(24 Suppl):23-7. doi: 10.2217/fon.15.312.
9
CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.CheckMate 743：恶性胸膜间皮瘤的一线希望
Clin Lung Cancer. 2021 Mar;22(2):71-73. doi: 10.1016/j.cllc.2020.11.009. Epub 2020 Dec 2.
10
Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.胸膜内免疫疗法：胸膜恶性肿瘤新兴治疗策略的最新进展
Clin Respir J. 2019 May;13(5):272-279. doi: 10.1111/crj.13010. Epub 2019 Mar 24.
引用本文的文献
1
Pleural mesothelioma patients and ex-exposed asbestos workers are immunologically poor responders to oncogenic Merkel cell polyomavirus.胸膜间皮瘤患者和曾经接触过石棉的工人对致癌性默克尔细胞多瘤病毒的免疫反应较差。
Transl Lung Cancer Res. 2025 Jul 31;14(7):2611-2625. doi: 10.21037/tlcr-2025-198. Epub 2025 Jul 28.
本文引用的文献
1
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.广泛胸膜切除术和化疗与单纯化疗治疗胸膜间皮瘤（MARS 2）：一项 3 期随机对照试验。
Lancet Respir Med. 2024 Jun;12(6):457-466. doi: 10.1016/S2213-2600(24)00119-X. Epub 2024 May 10.
2
ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis.ROB-ME：一种用于评估在进行Meta分析的系统评价中因证据缺失导致的偏倚风险的工具。
BMJ. 2023 Nov 20;383:e076754. doi: 10.1136/bmj-2023-076754.
3
Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades.1990年至2019年间全球、区域和国家间间皮瘤负担的趋势以及未来二十年的预测。
SSM Popul Health. 2023 Jun 3;23:101441. doi: 10.1016/j.ssmph.2023.101441. eCollection 2023 Sep.
4
Assessment of Global Trends in the Diagnosis of Mesothelioma From 1990 to 2017.1990年至2017年间间皮瘤诊断的全球趋势评估。
JAMA Netw Open. 2021 Aug 2;4(8):e2120360. doi: 10.1001/jamanetworkopen.2021.20360.
5
Controversies in the role of radiotherapy in pleural mesothelioma.放射治疗在胸膜间皮瘤中的作用争议
Transl Lung Cancer Res. 2021 Apr;10(4):2079-2087. doi: 10.21037/tlcr-20-583.
6
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.比较单药或联合免疫检查点抑制剂与一线含或不含贝伐珠单抗的铂类化疗方案用于晚期非小细胞肺癌患者。
Cochrane Database Syst Rev. 2021 Apr 30;4(4):CD013257. doi: 10.1002/14651858.CD013257.pub3.
7
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
8
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.一线纳武利尤单抗联合伊匹单抗治疗不可切除恶性胸膜间皮瘤（CheckMate 743）：一项多中心、随机、开放标签、III 期临床试验。
Lancet. 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. Epub 2021 Jan 21.
9
CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.CheckMate 743：恶性胸膜间皮瘤的一线希望
Clin Lung Cancer. 2021 Mar;22(2):71-73. doi: 10.1016/j.cllc.2020.11.009. Epub 2020 Dec 2.
10
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma.生物标志物引导的恶性胸膜间皮瘤靶向治疗与免疫治疗
Ther Adv Med Oncol. 2020 Nov 12;12:1758835920971421. doi: 10.1177/1758835920971421. eCollection 2020.
Zotero 插件